AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

Clinical-stage drug development offers big rewards—and big risks. | This week on "The Top Line," we dive into several of the ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

DelveInsight's Transmucosal Drugs Market Insights report provides the current and forecast market analysis, individual leading transmucosal drugs companies' market shares, challenges, transmucosal ...

Responding to a lawsuit by Novartis (NVS), the U.S. Department of Justice has defended Medicare price negotiations, signaling ...

AbbVie and Xilio Therapeutics have announced a partnership worth over $2.1bn to develop tumour-activated, antibody-based immunotherapies. The collaboration and option-to-licence agreement will include ...

Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 ...

Dr. Mehmet Oz holds millions of dollars worth of shares in health insurance, fertility, pharmaceutical and vitamin companies.

BLCO may be sold in 2025 to service the debt of majority shareholder BHC, and any sale will be at a premium to the current ...